Combination method for treatment of cancer

Abstract

The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.

1 . A method for the treatment of cancer in a subject, the method comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection to a tumor or systemic administration to the subject in combination with the co-administration of an immuno-stimulatory agent via the systemic route to the subject. 
     
     
         2 . The method of  claim 1 , wherein the oncolytic virus or oncolytic viral RNA is selected from the group consisting of Family Picornaviridae. 
     
     
         3 . The method of  claim 1 , wherein the oncolytic virus or oncolytic viral RNA selected from the group consisting of Family Picornaviridae virus that bind to intercellular adhesion molecule-1 (ICAM-1) and/or decay-accelerating factor (DAF) on the surface of the tumour cell. 
     
     
         4 . The method of  claim 1 , wherein the oncolytic virus or oncolytic viral RNA is selected from the group consisting of genus enterovirus that bind to intercellular adhesion molecule-1 (ICAM-1) and/or decay-accelerating factor (DAF) on the surface of the tumour cell. 
     
     
         5 . The method of  claim 1 , wherein the oncolytic virus or oncolytic viral RNA is selected from the group consisting of Group A Coxsackievirus that bind to intercellular adhesion molecule-1 (ICAM-1) and/or decay-accelerating factor (DAF) on the surface of the tumour cell. 
     
     
         6 . The method of  claim 1 , wherein the oncolytic virus or oncolytic viral RNA is Coxsackievirus A21. 
     
     
         7 . The method of  claim 1 , wherein the immunostimulatory agent is selected from the group consisting of an agent that specifically binds to the surface expressed PD-1, PD-L1, PD-L2, CTLA-4 or OX-40. 
     
     
         8 . The method of  claim 1 , wherein the immunostimulatory agent is selected from the group consisting of a monoclonal antibody that specifically binds to the surface expressed PD-1, PD-L1, PD-L2, CTLA-4 or OX-40. 
     
     
         9 . The method of  claim 1 , wherein delivering the oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration is prior to the administration of an immuno-stimulatory agent via the systemic route. 
     
     
         10 . The method of  claim 1 , wherein delivering the oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration is following the administration of an immuno-stimulatory agent via the systemic route to the subject. 
     
     
         11 . The method of  claim 1 , wherein the cancer or tumour is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, lymphoid cancer, leukemia, brain cancer, lung cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, stomach cancer, intestinal cancer, bladder cancer, cancer of the kidney, multiple myeloma, non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma and melanoma. 
     
     
         12 . The method of  claim 1 , wherein the cancer or tumour is melanoma. 
     
     
         13 . The method according to  claim 1 , wherein the subject is a human. 
     
     
         14 . The method of  claim 1 , wherein the immunostimulatory agent is an agent that targets an immune checkpoint molecule selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, CD134, CD134L, CD137, CD137L, CD80, CD86, B7-H3, B7-H4, B7RP1, ICOS, TIM3, GAL9, CD28 and OX-40. 
     
     
         15 . The method of  claim 1 , wherein the cancer is bladder cancer. 
     
     
         16 . The method of  claim 15 , wherein delivering the oncolytic virus or oncolytic viral RNA to the subject is via intravesicular administration. 
     
     
         17 . The method of  claim 15 , wherein the immunostimulatory agent is selected from the group consisting of a monoclonal antibody that specifically binds to the surface expressed PD-1, PD-L1, PD-L2, or CTLA-4.